SCHEMBL6741864

SCHEMBL6741864

C=CCOc1cc(CNc2nc(C)nc(C)c2Cl)ccc1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.42
POLB P06746 2/20 0.42
KDM4E B2RXH2 6/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 2/20 0.39
KMT2A Q03164 5/20 0.38
MAPT P10636 4/20 0.38
GAA P10253 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP2D6 P10635 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 2/20 0.38
G6PD P11413 1/20 0.37
TSHR P16473 2/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX5 P09917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6739651 0.85 KMT2A (0.47) ALDH1A1POLBKDM4EHPGDKMT2A
SCHEMBL6742507 0.84 MAPT (0.36) ALDH1A1KDM4EKMT2AMAPTGAA
SCHEMBL6742315 0.84 KMT2A (0.46) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL6740326 0.83 ALDH1A1 (0.37) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL6743861 0.81 TSHR (0.39) ALDH1A1POLBKDM4EHPGDKMT2A
SCHEMBL6740970 0.80 ALPL (0.43) KMT2ANPSR1HSD17B10ALPLALPG
SCHEMBL6743539 0.78 CCNB2 (0.47) LMNAKMT2AGAAMEN1TSHR
SCHEMBL6746130 0.78 ALPL (0.42) KMT2AHSD17B10ALPLALPGPLAA
SCHEMBL6743052 0.74 ESR1 (0.49) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL6846143 0.73 ALDH1A1 (0.33) ALDH1A1POLBKDM4EHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818642-B2 CAMPYLOBACTER INFECTION TREATMENT ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040152714-A1 Benzylaminopyrimidines ALTANA PHARMA AG (DE) 2004-08-05 US disclosed
EP-1395594-A1 NEW BENZYLAMINOPYRIMIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2004-03-10 EP disclosed
WO-2002094832-A1 NEW BENZYLAMINOPYRIMIDINES ALTANA PHARMA AG (DE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152714-A1 Benzylaminopyrimidines DPYD, PGLS, TPMT ALDH1A1 355/4885POLB 498/4885KDM4E 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.